Plitidepsin 1.5 mg / day
DrugPlitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
NCT Number: NCT05121740
The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study. APLICOV-PC study was a multicenter, randomized, proof-of-concept clinical trial to assess the safety profile of 3 different dose levels of plitidepsin (1,5 mg, 2,0 mg and 2,5 mg) administered three consecutive days, in adult patients with confirmed diagnosis of COVID-19 who require hospital admission.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
The APLICOV-PC proof of concept study demonstrated the antiviral activity of plitidepsin in terms of reducing viral load, inducing recovery, and impact on lymphocyte reconstitution and other inflammatory parameters.
A percentage of patients, which varies between 10 and 25%, continue to show symptoms at 3 months after contracting the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: For some of them this significantly restricts their life, requiring them to take long-term sickness leave from work, and leaving them with sequelae that may continue for more than one year.
With this study, Pharmamar intends to evaluate whether the treatment with plitidepsin, by attaining a reduction in the viral load and a faster recovery of the patient, could have a relevant impact on the emergence of sequelae resulting from the SARS-CoV-2 infection.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).
Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).
Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).
Time frame: Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.
Number and percentage of patients who developed complications related to post COVID-19 infection
Time frame: Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.
Percentage of patients requiring oxygen therapy
Time frame: Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months..
Percentage of patients with complications Post COVID-19 Infection (Regardless Relationship, i.e. Related to COVID-19 Infection or Not).
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
PaO2/FiO2 (Ratio of partial pressure arterial oxygen and fraction of inspired oxygen) mean, standard deviation.
PaO2/FiO2 ratio to evaluate disease severity and discriminate between 'Moderate' and 'Severe' categories according to FDA guidance.
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
FEV1 (Forced expiratory volume 1) mean, standard deviation.
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
Lung difussion testing: mean and standard deviation. Unit of measure: % reference theoretical value
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
Percentage of patients with alterations in chest radiography
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
Percentage of patients with electrocardiogram alterations
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
Percentage of patients with ≥grade 2 alterations in laboratory parameters Grade measured according to NCI-CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events version 5.0) where Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL* Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
Percentage of patients in each category of the Modified Medical Research Council (mMRC) dyspnea scale.
The mMRC scale is a self-rating tool to measure the degree of disability that breathlessness poses on day-to-day activities on a scale from 0 to 4:
0, no breathlessness except on strenuous exercise;
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
FEV1/FVC mean, standard deviation.
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
FVC mean, standard deviation.
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
SaO2 (Arterial oxygen saturation) mean, standard deviation. Unit of measure: percentage of oxygen saturation
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
The Barthel index measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing.
Percentage of patients at each category according to the score obtained: 0-20: Total dependence; 21-60: Severe dependence; 61-90: Moderate dependence; 91-99: Low dependence; 100: Independence
Time frame: Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.
Percentage of patients requiring hospital readmission
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
minute walking test mean, standard deviation. Total distance measured in meters (m)
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
minute walking test mean, standard deviation. Expected distance (the predicted distance that a patient could walk) measured in meters (m)
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
6 minute walking test mean, standard deviation. Unit of measure: Percentage of predicted distance
Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.
6 minute walking test mean, standard deviation. Unit of measure: Number of laps of 60 m
PharmaMar
Industry
Extension Study in a Cohort of Adult Patients With SARS-CoV-2 Infection Requiring Hospital Admission and Received Treatment With Plitidepsin in the APLICOV-PC Study
Acronym: E-APLICOV-PC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07552779
COVID-19, COVID-19 (Coronavirus Disease 2019)
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial DetailsNCT06194357
Behavior, COVID-19
Hong Kong
View Trial DetailsNCT04639466
COVID-19, COVID-19 Infection
Claremont, California, United States
View Trial DetailsNCT04355533
COVID-19, COVID-19 Infection
Paris, France
View Trial Details